​

Avalo Therapeutics (AVTX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

AVTX Stock Forecast

Avalo Therapeutics (AVTX) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $45.13, with a high of $60.00 and a low of $30.00. This represents a 194.97% increase from the last price of $15.30.

- $12 $24 $36 $48 $60 High: $60 Avg: $45.13 Low: $30 Last Closed Price: $15.3

AVTX Stock Rating

Avalo Therapeutics stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (80.00%), 1 Hold (10.00%), 1 Sell (10.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 1 1 8 Strong Sell Sell Hold Buy Strong Buy

AVTX Price Target Upside V Benchmarks

TypeNameUpside
StockAvalo Therapeutics194.97%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-311
Avg Price Target-$38.67$44.09
Last Closing Price$15.30$15.30$15.30
Upside/Downside-152.75%188.17%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 26213---15
Aug, 26213---15
Jul, 26212---14
Jun, 26211---13
May, 26211---13
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 07, 2026Guggenheim$48.00$18.70156.68%213.73%
Aug 07, 2026H.C. Wainwright$30.00$18.7060.43%96.08%
Jul 06, 2026Leerink Partners$38.00$19.8091.92%148.37%
May 14, 2026Wedbush$34.00$19.4674.72%122.22%
May 14, 2026Mizuho Securities$45.00$19.85126.70%194.12%
May 14, 2026H.C. Wainwright$35.00$19.8576.32%128.76%
May 11, 2026Piper Sandler$60.00$21.57178.16%292.16%
May 06, 2026BTIG$58.00$16.26256.70%279.08%
Apr 08, 2026Wolfe Research$48.00$14.41233.10%213.73%
Feb 02, 2026Guggenheim$50.00$15.11230.91%226.80%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 16, 2026Cantor FitzgeraldOverweightOverweighthold
Jul 24, 2026Cantor FitzgeraldOverweightOverweighthold
Jun 12, 2026Bank of America SecuritiesBuyinitialise
May 11, 2026Piper SandlerOverweightOverweighthold
May 06, 2026BTIGBuyBuyhold
May 06, 2026CitigroupOutperformOutperformhold
Apr 08, 2026Wolfe ResearchOutperforminitialise
Mar 25, 2026H.C. WainwrightBuyBuyhold
Feb 02, 2026GuggenheimBuyinitialise
Sep 17, 2025H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-3K $-2K $-2K $-1K $-500 $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.33K$-1.06K$-113.58$-4.32$-5.84---
Avg Forecast$-2.26K$-698.40$-96.00$-25.79$-5.31$-4.30$-4.48$-3.08
High Forecast$-2.26K$-691.71$-96.00$-2.22$-5.10$-1.66$-4.48$-3.08
Low Forecast$-2.26K$-711.78$-96.00$-49.35$-5.51$-6.35$-4.48$-3.08
Surprise %3.22%52.15%18.31%-83.25%9.98%---

Revenue Forecast

$0 $5M $10M $15M $20M $25M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$5.40M$18.05M$1.92M$441.00K$59.00K---
Avg Forecast$6.08M$20.80M$1.70M$150.00K$1.00M$1.00M$1.00M$1.71M
High Forecast$6.08M$21.10M$1.70M$163.04K$1.00M$1.00M$1.00M$1.71M
Low Forecast$6.08M$20.64M$1.70M$130.43K$1.00M$1.00M$1.00M$1.71M
Surprise %-11.28%-13.20%13.18%194.00%-94.10%---

Net Income Forecast

$-650M $-520M $-390M $-260M $-130M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-84.38M$-41.66M$-31.54M$-35.13M$-78.26M---
Avg Forecast$-627.09M$-193.97M$-26.66M$-8.13M$-1.47M$-1.11M$-1.24M$-854.01K
High Forecast$-627.09M$-192.11M$-26.66M$-615.98K$-1.42M$-461.46K$-1.24M$-854.01K
Low Forecast$-627.09M$-197.68M$-26.66M$-13.71M$-1.53M$-1.76M$-1.24M$-854.01K
Surprise %-86.54%-78.52%18.31%331.83%5209.15%---

AVTX Forecast FAQ

Is Avalo Therapeutics stock a buy?

Avalo Therapeutics stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 1 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Avalo Therapeutics is a favorable investment for most analysts.

What is Avalo Therapeutics's price target?

Avalo Therapeutics's price target, set by 10 Wall Street analysts, averages $45.13 over the next 12 months. The price target range spans from $30 at the low end to $60 at the high end, suggesting a potential 194.97% change from the previous closing price of $15.3.

How does Avalo Therapeutics stock forecast compare to its benchmarks?

Avalo Therapeutics's stock forecast shows a 194.97% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Avalo Therapeutics over the past three months?

  • September 2026: 13.33% Strong Buy, 86.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 13.33% Strong Buy, 86.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Avalo Therapeutics’s EPS forecast?

Avalo Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-4.3, marking a -26.37% decrease from the reported $-5.84 in 2025. Estimates for the following years are $-4.48 in 2027, and $-3.08 in 2028.

What is Avalo Therapeutics’s revenue forecast?

Avalo Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $1M, reflecting a 1594.92% increase from the reported $59K in 2025. The forecast for 2027 is $1M, and $1.71M for 2028.

What is Avalo Therapeutics’s net income forecast?

Avalo Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-1.113M, representing a -98.58% decrease from the reported $-78.259M in 2025. Projections indicate $-1.244M in 2027, and $-854K in 2028.